Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?

Noris M, Remuzzi G.

Kidney Int. 2019 Jul;96(1):13-15. doi: 10.1016/j.kint.2019.02.038.

PMID:
31229026
2.

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.

Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2019 May 1;10:853. doi: 10.3389/fimmu.2019.00853. eCollection 2019.

3.

C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.

Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G; EAGLE Study Group.

Am J Kidney Dis. 2019 Mar 28. pii: S0272-6386(19)30100-3. doi: 10.1053/j.ajkd.2018.12.046. [Epub ahead of print]

PMID:
30929851
4.

Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C.

Nephron. 2019;142(3):264-270. doi: 10.1159/000497823. Epub 2019 Mar 19.

PMID:
30889567
5.

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.

Am J Kidney Dis. 2019 Jul;74(1):56-72. doi: 10.1053/j.ajkd.2018.11.012. Epub 2019 Mar 7.

PMID:
30851964
6.

Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation.

Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, Fiori S, Rota C, Karachi A, Carrara C, Noris M, Perico N, Remuzzi G.

Transplantation. 2019 Jun;103(6):1121-1130. doi: 10.1097/TP.0000000000002611.

PMID:
30801518
7.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM.

Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review.

PMID:
30692664
8.

Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.

9.

Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.

Noris M, Donadelli R, Remuzzi G.

Pediatr Nephrol. 2019 Aug;34(8):1311-1323. doi: 10.1007/s00467-018-3989-0. Epub 2018 Jun 9. Review.

PMID:
29948306
10.

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ.

J Immunol. 2018 Apr 1;200(7):2464-2478. doi: 10.4049/jimmunol.1701695. Epub 2018 Mar 2.

11.

Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?

Noris M, Ruggenenti P, Remuzzi G.

Am J Kidney Dis. 2017 Dec;70(6):754-757. doi: 10.1053/j.ajkd.2017.08.005. No abstract available.

PMID:
29169515
12.

Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function.

Perico L, Morigi M, Rota C, Breno M, Mele C, Noris M, Introna M, Capelli C, Longaretti L, Rottoli D, Conti S, Corna D, Remuzzi G, Benigni A.

Nat Commun. 2017 Oct 17;8(1):983. doi: 10.1038/s41467-017-00937-2.

13.

Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy; Nastasi.

J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258. Epub 2017 Oct 13.

14.

Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.

Goicoechea de Jorge E, Tortajada A, García SP, Gastoldi S, Merinero HM, García-Fernández J, Arjona E, Cao M, Remuzzi G, Noris M, Rodríguez de Córdoba S.

J Am Soc Nephrol. 2018 Jan;29(1):240-249. doi: 10.1681/ASN.2017050518. Epub 2017 Oct 9.

15.

Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival.

Aiello S, Rocchetta F, Longaretti L, Faravelli S, Todeschini M, Cassis L, Pezzuto F, Tomasoni S, Azzollini N, Mister M, Mele C, Conti S, Breno M, Remuzzi G, Noris M, Benigni A.

Sci Rep. 2017 Sep 14;7(1):11518. doi: 10.1038/s41598-017-08617-3.

16.

Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement.

Noris M, Remuzzi G.

Semin Nephrol. 2017 Sep;37(5):447-463. doi: 10.1016/j.semnephrol.2017.05.018. Review.

PMID:
28863792
17.

Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.

Bettoni S, Galbusera M, Gastoldi S, Donadelli R, Tentori C, Spartà G, Bresin E, Mele C, Alberti M, Tortajada A, Yebenes H, Remuzzi G, Noris M.

J Immunol. 2017 Aug 1;199(3):1021-1040. doi: 10.4049/jimmunol.1601121. Epub 2017 Jun 26.

18.

Hemolytic Uremic Syndrome in Pregnancy and Postpartum.

Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F.

Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1237-1247. doi: 10.2215/CJN.00280117. Epub 2017 Jun 8.

19.

Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase.

Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R.

J Biol Chem. 2017 Apr 14;292(15):6094. doi: 10.1074/jbc.A115.693119. No abstract available.

20.

Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response.

Casiraghi F, Azzollini N, Todeschini M, Fiori S, Cavinato RA, Cassis P, Solini S, Pezzuto F, Mister M, Thurman JM, Benigni A, Remuzzi G, Noris M.

Am J Transplant. 2017 Sep;17(9):2312-2325. doi: 10.1111/ajt.14262. Epub 2017 Apr 10.

21.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants.

Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.

22.

Immunochip analysis identifies novel susceptibility loci in the human leukocyte antigen region for acquired thrombotic thrombocytopenic purpura.

Mancini I, Ricaño-Ponce I, Pappalardo E, Cairo A, Gorski MM, Casoli G, Ferrari B, Alberti M, Mikovic D, Noris M, Wijmenga C, Peyvandi F; Italian Group of TTP Investigators.

J Thromb Haemost. 2016 Dec;14(12):2356-2367. doi: 10.1111/jth.13548. Epub 2016 Dec 3.

23.

Genetic Atypical Hemolytic-Uremic Syndrome.

Noris M, Bresin E, Mele C, Remuzzi G.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2007 Nov 16 [updated 2016 Jun 9].

24.

Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.

Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R.

J Biol Chem. 2016 Apr 8;291(15):8214-30. doi: 10.1074/jbc.M115.693119. Epub 2016 Feb 22. Retraction in: J Biol Chem. 2017 Apr 14;292(15):6094.

25.

Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G.

Mol Immunol. 2016 Mar;71:131-142. doi: 10.1016/j.molimm.2016.01.010. Epub 2016 Feb 16.

PMID:
26895476
26.

Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.

Peyvandi F, Rossio R, Ferrari B, Lotta LA, Pontiggia S, Ghiringhelli Borsa N, Pizzuti M, Donadelli R, Piras R, Cugno M, Noris M.

J Thromb Haemost. 2016 Feb;14(2):340-5. doi: 10.1111/jth.13210. Epub 2016 Feb 1.

27.

Liver transplantation for aHUS: still needed in the eculizumab era?

Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G.

Pediatr Nephrol. 2016 May;31(5):759-68. doi: 10.1007/s00467-015-3278-0. Epub 2015 Nov 24.

28.

Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab.

Pecoraro C, Ferretti AV, Rurali E, Galbusera M, Noris M, Remuzzi G.

Am J Kidney Dis. 2015 Dec;66(6):1067-70. doi: 10.1053/j.ajkd.2015.06.032. Epub 2015 Sep 26.

PMID:
26409664
29.

Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases.

Recalde S, Tortajada A, Subias M, Anter J, Blasco M, Maranta R, Coco R, Pinto S, Noris M, García-Layana A, Rodríguez de Córdoba S.

J Am Soc Nephrol. 2016 May;27(5):1305-11. doi: 10.1681/ASN.2015050580. Epub 2015 Sep 16.

30.

ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.

Rurali E, Banterla F, Donadelli R, Bresin E, Galbusera M, Gastoldi S, Peyvandi F, Underwood M, Remuzzi G, Noris M.

Clin J Am Soc Nephrol. 2015 Nov 6;10(11):2002-12. doi: 10.2215/CJN.01700215. Epub 2015 Sep 4.

31.

Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population.

Fratelli M, Bolis M, Kurosaki M, Dori M, Guarnaccia V, Spinelli O, Alberti M, Valoti E, Pileggi S, Noris M, Remuzzi G, Rambaldi A, Terao M, Garattini E.

Leuk Lymphoma. 2016 May;57(5):1234-7. doi: 10.3109/10428194.2015.1082180. Epub 2016 Mar 2. No abstract available.

PMID:
26317246
32.

Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015.

Noris M, Remuzzi G.

Am J Kidney Dis. 2015 Aug;66(2):359-75. doi: 10.1053/j.ajkd.2015.03.040. Epub 2015 May 29. Review. No abstract available.

33.

The role of complement in C3 glomerulopathy.

Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Córdoba SR, Noris M, Pickering M, Smith R.

Mol Immunol. 2015 Sep;67(1):21-30. doi: 10.1016/j.molimm.2015.03.012. Epub 2015 Apr 28. Review.

PMID:
25929733
34.

Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome.

Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, Bick D, Helbling D, Veith R, Valoti E, Donadelli R, Murer L, Neunhäuserer M, Breno M, Frémeaux-Bacchi V, Lifton R, Remuzzi G, Noris M.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1011-9. doi: 10.2215/CJN.08520814. Epub 2015 Apr 8.

35.

Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.

Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, Sina F, Mele C, Iatropoulos P, Grassi T, Fotia V, Romualdi C, Martini P, Noris M, Paracchini L, Craparotta I, Petrillo M, Milani R, Perego P, Ravaggi A, Zambelli A, Ronchetti E, D'Incalci M, Marchini S.

Ann Oncol. 2015 Jul;26(7):1363-71. doi: 10.1093/annonc/mdv164. Epub 2015 Apr 6.

PMID:
25846551
36.

Atypical aHUS: State of the art.

Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ.

Mol Immunol. 2015 Sep;67(1):31-42. doi: 10.1016/j.molimm.2015.03.246. Epub 2015 Apr 3. Review.

PMID:
25843230
37.

Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJ, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V.

Blood. 2015 Apr 9;125(15):2359-69. doi: 10.1182/blood-2014-10-609073. Epub 2015 Jan 21.

38.

Podocyte dysfunction in atypical haemolytic uraemic syndrome.

Noris M, Mele C, Remuzzi G.

Nat Rev Nephrol. 2015 Apr;11(4):245-52. doi: 10.1038/nrneph.2014.250. Epub 2015 Jan 20. Review.

PMID:
25599621
39.

A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.

Subías M, Tortajada A, Gastoldi S, Galbusera M, López-Perrote A, Lopez Lde J, González-Fernández FA, Villegas-Martínez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodríguez de Córdoba S.

J Immunol. 2014 Dec 1;193(11):5567-75. doi: 10.4049/jimmunol.1402013. Epub 2014 Oct 29.

40.

Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.

Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, Schieppati A, Noris M, Tovo PA, Remuzzi G.

Pediatr Nephrol. 2015 Jan;30(1):167-72. doi: 10.1007/s00467-014-2944-y. Epub 2014 Aug 31.

PMID:
25173358
41.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.

Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.

42.

A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.

Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M.

J Am Soc Nephrol. 2015 Jan;26(1):209-19. doi: 10.1681/ASN.2013121339. Epub 2014 Jun 5.

43.

An unanticipated role for survivin in organ transplant damage.

Cassis P, Solini S, Azzollini N, Aiello S, Rocchetta F, Conti S, Novelli R, Gagliardini E, Mister M, Rapezzi F, Rapezzi S, Benigni A, Remuzzi G, Conway EM, Noris M.

Am J Transplant. 2014 May;14(5):1046-60. doi: 10.1111/ajt.12677. Epub 2014 Apr 14.

44.

Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?

Marinozzi MC, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A, Cayla M, Tabarin F, Jablonski M, Hue C, Smith RJ, Noris M, Halbwachs-Mecarelli L, Donadelli R, Fremeaux-Bacchi V, Roumenina LT.

J Am Soc Nephrol. 2014 Sep;25(9):2053-65. doi: 10.1681/ASN.2013070796. Epub 2014 Mar 20.

45.

Hemolytic uremic syndrome.

Mele C, Remuzzi G, Noris M.

Semin Immunopathol. 2014 Jul;36(4):399-420. doi: 10.1007/s00281-014-0416-x. Epub 2014 Feb 14. Review.

PMID:
24526222
46.

Kidney transplantation from a donor with acute kidney injury: an unexpected outcome.

Mescia F, Piras R, Noris M, Marchetti G, Rossini G, Remuzzi G, Ruggenenti P.

Am J Transplant. 2014 Apr;14(4):977-8. doi: 10.1111/ajt.12648. Epub 2014 Feb 6. No abstract available.

47.

Cardiovascular complications in atypical haemolytic uraemic syndrome.

Noris M, Remuzzi G.

Nat Rev Nephrol. 2014 Mar;10(3):174-80. doi: 10.1038/nrneph.2013.280. Epub 2014 Jan 14. Review.

PMID:
24419569
48.

Overview of complement activation and regulation.

Noris M, Remuzzi G.

Semin Nephrol. 2013 Nov;33(6):479-92. doi: 10.1016/j.semnephrol.2013.08.001. Review.

49.

Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Noris M, Remuzzi G.

Curr Opin Nephrol Hypertens. 2013 Nov;22(6):704-12. doi: 10.1097/MNH.0b013e328365b3fe. Review.

PMID:
24076560
50.

In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.

Todeschini M, Cortinovis M, Perico N, Poli F, Innocente A, Cavinato RA, Gotti E, Ruggenenti P, Gaspari F, Noris M, Remuzzi G, Casiraghi F.

J Immunol. 2013 Sep 1;191(5):2818-28. doi: 10.4049/jimmunol.1203261. Epub 2013 Aug 2.

Supplemental Content

Support Center